Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that calcitriol-resistant rickets is associated with alopecia in children and should be considered in the differential diagnosis of hair loss.

This study reports previously unreported nail features in Cronkhite-Canada syndrome, specifically recurrent onychomadesis of all 20 nails linked to systemic illness.

This review presents an objective analysis of female androgenetic alopecia, discussing clinical and dermoscopic examination approaches but reports no new clinical findings.

This article discusses the potential benefits of GcMAF and oral MAF, developed by "Saisei Mirai", for cancer and other conditions, but reports no new clinical results.

This study found that deleting Stim1 and Stim2 in mature T regulatory cells disrupts Ca 2+ signaling, preventing their differentiation and leading to severe autoimmune disorders in mice.

This study observed that the degradation product PTeCA significantly increased in hair treated with oxidative cosmetics, suggesting it could be a reliable marker for detecting such treatments, with a proposed PTCA cut-off value using PTeCA as the gold standard.

In this prospective cohort, baseline severity, disease activity, and relapse history were identified as key factors influencing response and recurrence in alopecia areata, suggesting that implementing standardized assessments could enhance risk stratification and personalized care approaches.

This study observed that Black women with central centrifugal cicatricial alopecia had a higher prevalence of uterine leiomyomas compared to those with lichen planopilaris, suggesting a potential association between the conditions.

This study provides suggestive evidence that duplications in the MCHR2 gene may be involved in the pathogenesis of alopecia areata.

This review discusses the overlapping clinical features and diagnostic challenges of non-classic adrenal hyperplasia and polycystic ovary syndrome without presenting original research findings.

This case report describes a patient with Cronkhite–Canada syndrome, where immunosuppression and nutritional support led to disease remission.

In this study, dry powder inhalers containing Cepharanthine were administered to rats with acute lung injury, significantly reducing pulmonary edema, hemorrhage, and inflammatory markers, suggesting its potential as an effective anti-inflammatory treatment when inhaled directly into the lungs.

This case report identifies a novel association between Graham Little–Piccardi–Lassueur syndrome and complete androgen insensitivity syndrome, suggesting the influence of androgens in the alopecias accompanying the former may be limited.

This case study describes the successful treatment of a 13-year-old girl with relapsing polychondritis and autoimmune symptoms using co-trimoxazole, highlighting its potential role in managing autoimmune diseases.

This case report highlighted a rare occurrence of both adrenocortical carcinoma and uric acid kidney stones in a 5-year-old boy, with hormonal levels and clinical symptoms returning to normal after treatment and no recurrence over four years, emphasizing comprehensive endocrine evaluations in pediatric ACC management.

This case report describes a 19-year-old patient with microsatellite stable adrenocortical carcinoma who showed a promising 36-month response to pembrolizumab, including structural and biochemical improvements, with primary adrenal insufficiency as a major side effect.

This report highlights a case of disseminated and recurrent infundibulofolliculitis in a 45-year-old African American male and underscores the importance of performing a skin biopsy for diagnosis.

This study describes and characterizes four cases of alopecia areata induced by immune checkpoint inhibitor therapy in cancer patients, highlighting the importance of recognizing and managing these hair-related adverse events.

This study found that dermoscopy-guided scalp biopsies provided a definitive pathological diagnosis in 95% of patients with cicatricial alopecia.

This study found that treatment with ritlecitinib or brepocitinib was effective in improving scalp hair loss for patients with alopecia areata over 24 weeks compared to placebo.

In this study, patients with alopecia areata who didn't initially respond to ritlecitinib at Week 24 showed improved response rates by Week 48, with up to 34% achieving better hair regrowth outcomes.

This review suggests that platelet-rich plasma may be a promising treatment for immune-mediated alopecias, including alopecia areata and primary cicatricial alopecias, but definitive recommendations are limited due to insufficient high-quality evidence.

Corticosteroids improved symptoms in a man with Cronkhite-Canada Syndrome.

This review discusses the challenges in diagnosing primary cicatricial alopecias and explores how improved communication and digital pathology could enhance diagnosis, but it reports no new clinical results.

This report describes early and late stages of central centrifugal cicatricial alopecia in two Black women, highlighting progression from a small to a large central patch of hair loss.

This review by Aceituno et al. found that both baricitinib and ritlecitinib demonstrate strong efficacy for severe alopecia areata, with meaningful hair regrowth by Week 24, but notes limitations like differing trial sizes and potential effect size overestimations.

This update of the 2023 International Guideline for PCOS offers refined diagnostic criteria and management recommendations, emphasizing evidence-based care, but notes that research quality remains low to moderate.

In this study, rheumatoid arthritis patients showed no changes in the number of circulating follicular helper T cells, but these cells had increased CD200 expression, implicating them in disease pathogenesis and suggesting CD200/CD200R as a potential therapeutic target.

This study investigated AHR signaling's role in skin biology and reported that novel AHR ligands may help restore keratinocyte function and reduce inflammation in skin diseases, suggesting their potential as therapeutic agents.

This study observed that adolescents with alopecia areata receiving ritlecitinib 50 mg daily showed notable hair regrowth over three years, as seen in both clinician- and patient-reported outcomes. However, the decreased number of participants at later stages limits the findings.